A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)
Status:
Completed
Trial end date:
2014-05-12
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the influence of hepatic insufficiency on the
pharmacokinetics (PK) of doravirine (MK-1439). In Part 1, PK of doravirine in participants
with moderate hepatic insufficiency was compared with that of healthy control subjects
matched with regard to mean age and weight. If a clinically meaningful increase in exposure
of doravirine was observed in participants with moderate hepatic insufficiency in Part 1,
study Part 2 was to evaluate PK of doravirine in participants with mild hepatic
insufficiency.